◀ Back to IRF6

IRF6 — LIPA

Text-mined interactions from Literome

Duan et al., Int Immunopharmacol 2010 (Acute Lung Injury...) : Here we synthesized a novel MD-2 mimetic peptide ( MDMP ), derived from the putative LPS binding domain and TLR4 binding domain of MD-2, and found that MDMP dose-dependently bound to LPS and inhibited LPS activated Limulus amebocyte lysate (LAL)
Sturk et al., Prog Clin Biol Res 1987 : The assay is based upon the LPS dependent activation of Limulus amebocyte lysate (LAL) , and the subsequent measurement of the activated enzyme with a chromogenic substrate
Hosotsubo et al., Crit Care Med 1985 (Hyperlipidemias) : A positive LAL in saline required minimum LPS and mannan concentrations of 10 ( -11 ) and 10 ( -5 ) g/ml, respectively, while the minimum concentrations premixed with plasma were 10 ( -13 ) and 10 ( -9 ) g/ml, respectively
Roth et al., Prog Clin Biol Res 1994 : Interaction of LPS with Hb was also associated with markedly increased biological activity of LPS, as manifested by enhancement of LPS activation of Limulus amebocyte lysate (LAL) , increased release of human mononuclear cell tissue factor, and enhanced production of human endothelial cell tissue factor
Roth et al., Artif Cells Blood Substit Immobil Biotechnol 1994 : Interaction of LPS with SFH was also associated with markedly increased biological activity of LPS, as manifested by enhancement of LPS activation of Limulus amebocyte lysate (LAL) , increased release of human mononuclear cell tissue factor, and enhanced production of cultured human endothelial cell tissue factor